Literature DB >> 12021250

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Kitt Falk Petersen1, Elif Arioglu Oral, Sylvie Dufour, Douglas Befroy, Charlotte Ariyan, Chunli Yu, Gary W Cline, Alex M DePaoli, Simeon I Taylor, Phillip Gorden, Gerald I Shulman.   

Abstract

Lipodystrophy is a rare disorder that is characterized by selective loss of subcutaneous and visceral fat and is associated with hypertriglyceridemia, hepatomegaly, and disordered glucose metabolism. It has recently been shown that chronic leptin treatment ameliorates these abnormalities. Here we show that chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in severely insulin-resistant lipodystrophic patients. This improvement in insulin action was associated with a marked reduction in hepatic and muscle triglyceride content. These data suggest that leptin may represent an important new therapy to reverse the severe hepatic and muscle insulin resistance and associated hepatic steatosis in patients with lipodystrophy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021250      PMCID: PMC150981          DOI: 10.1172/JCI15001

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  Lipoatrophy revisited.

Authors:  M L Reitman; E Arioglu; O Gavrilova; S I Taylor
Journal:  Trends Endocrinol Metab       Date:  2000-12       Impact factor: 12.015

Review 2.  Cellular mechanisms of insulin resistance.

Authors:  G I Shulman
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

3.  Metabolic and endocrine studies in a case of lipoatrophic diabetes.

Authors:  A A Rossini; J Self; T T Aoki; R F Goldman; S R Newmark; M M Meguid; J S Soeldner; G F Cahill
Journal:  Metabolism       Date:  1977-06       Impact factor: 8.694

4.  Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.

Authors:  L Ryysy; A M Häkkinen; T Goto; S Vehkavaara; J Westerbacka; J Halavaara; H Yki-Järvinen
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

5.  Mechanism of troglitazone action in type 2 diabetes.

Authors:  K F Petersen; M Krssak; S Inzucchi; G W Cline; S Dufour; G I Shulman
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

6.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance.

Authors:  J K Kim; J J Fillmore; Y Chen; C Yu; I K Moore; M Pypaert; E P Lutz; Y Kako; W Velez-Carrasco; I J Goldberg; J L Breslow; G I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

7.  Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle.

Authors:  V Lebon; S Dufour; K F Petersen; J Ren; B M Jucker; L A Slezak; G W Cline; D L Rothman; G I Shulman
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

8.  Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

Authors:  E Arioglu; J Duncan-Morin; N Sebring; K I Rother; N Gottlieb; J Lieberman; D Herion; D E Kleiner; J Reynolds; A Premkumar; A E Sumner; J Hoofnagle; M L Reitman; S I Taylor
Journal:  Ann Intern Med       Date:  2000-08-15       Impact factor: 25.391

9.  Leptin-replacement therapy for lipodystrophy.

Authors:  Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

10.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Authors:  Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

View more
  256 in total

1.  Leptin: a novel therapeutic role in lipodystrophy.

Authors:  D B Savage; S O'Rahilly
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

3.  Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Naoki Kumashiro; Derek M Erion; Dongyan Zhang; Mario Kahn; Sara A Beddow; Xin Chu; Christopher D Still; Glenn S Gerhard; Xianlin Han; James Dziura; Kitt Falk Petersen; Varman T Samuel; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 4.  The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans.

Authors:  Martin Krssak; Michael Roden
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

5.  The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.

Authors:  Kathleen Mulligan; Hootan Khatami; Jean-Marc Schwarz; Giorgos K Sakkas; Alex M DePaoli; Viva W Tai; Michael J Wen; Grace A Lee; Carl Grunfeld; Morris Schambelan
Journal:  J Clin Endocrinol Metab       Date:  2009-01-27       Impact factor: 5.958

6.  Lack of kinin B₁ receptor potentiates leptin action in the liver.

Authors:  Raphael Gomes Fonseca; Vicencia Micheline Sales; Eduardo Ropelle; Carlos Castilho Barros; Lila Oyama; Silvia Saiuli Iuki Ihara; Mário Jose Abdalla Saad; Ronaldo Carvalho Araújo; João Bosco Pesquero
Journal:  J Mol Med (Berl)       Date:  2013-02-06       Impact factor: 4.599

Review 7.  Lipid-induced insulin resistance in the liver: role of exercise.

Authors:  Christos S Katsanos
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

8.  Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance.

Authors:  Cheol Soo Choi; Jonathan J Fillmore; Jason K Kim; Zhen-Xiang Liu; Sheene Kim; Emily F Collier; Ameya Kulkarni; Alberto Distefano; Yu-Jin Hwang; Mario Kahn; Yan Chen; Chunli Yu; Irene K Moore; Richard M Reznick; Takamasa Higashimori; Gerald I Shulman
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

9.  Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.

Authors:  Rebecca J Brown; Areli Valencia; Megan Startzell; Elaine Cochran; Peter J Walter; H Martin Garraffo; Hongyi Cai; Ahmed M Gharib; Ronald Ouwerkerk; Amber B Courville; Shanna Bernstein; Robert J Brychta; Kong Y Chen; Mary Walter; Sungyoung Auh; Phillip Gorden
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

10.  PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity.

Authors:  Michihiro Matsumoto; Wataru Ogawa; Kazunori Akimoto; Hiroshi Inoue; Kazuaki Miyake; Kensuke Furukawa; Yoshitake Hayashi; Haruhisa Iguchi; Yasushi Matsuki; Ryuji Hiramatsu; Hitoshi Shimano; Nobuhiro Yamada; Shigeo Ohno; Masato Kasuga; Tetsuo Noda
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.